Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
06/09/20171:00PMPRNUSNeurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference Live Audio Webcast Will be on June 15, 2017 PR Newswire SAN DIEGO, June 9, 2017 SAN DIEGO, June 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences... More...>>
06/02/20179:25AMPRNUSNeurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkins...
Neurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkinson's Disease and Movement Disorders PR Newswire SAN DIEGO, June 2, 2017 SAN DIEGO, June 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the upcoming presentation... More...>>
06/01/20174:18PMPRNUSNeurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference Live Audio Webcast Will be on June 8, 2017 PR Newswire SAN DIEGO, June 1, 2017 SAN DIEGO, June 1, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will... More...>>
05/23/20174:01PMPRNUSNeurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome
Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome Study Provides Clear Path Forward for Future Pivotal Studies Company to Host Conference Call and Webcast Tuesday, May 23rd at 5:00 P.M. ET / 2:00 P.M. PT PR Newswire SAN DIEGO, May 23, 2017 SAN DIEGO, May 23, 2017 /PRNewswire/... More...>>
05/18/20174:05PMPRNUSNeurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017...
Neurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017 American Psychiatric Association Annual Meeting PR Newswire SAN DIEGO, May 18, 2017 SAN DIEGO, May 18, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced today the upcoming... More...>>
05/17/201712:00PMPRNUSAbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis
AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis - Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain - New hormone and ovulation data will also be... More...>>
05/11/20173:00PMPRNUSNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference Live Audio Webcast Will be on May 17, 2017 PR Newswire SAN DIEGO, May 11, 2017 SAN DIEGO, May 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences... More...>>
05/09/20174:01PMPRNUSNeurocrine Biosciences Reports First Quarter 2017 Results
Neurocrine Biosciences Reports First Quarter 2017 Results - Launched INGREZZA® Commercially after Approval by the U.S. Food and Drug Administration for the Treatment of Tardive Dyskinesia - Phase II Study Results of INGREZZA in Pediatric Tourette Syndrome Expected in May 2017 - Acquired U.S. and Canadian Rights to Opicapone... More...>>
05/03/20171:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results Conference Call and Webcast Scheduled for Tuesday, May 9, 2017 PR Newswire SAN DIEGO, May 3, 2017 SAN DIEGO, May 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report... More...>>
05/02/20175:04PMPRNUSNeurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes
Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes PR Newswire SAN DIEGO, May 2, 2017 SAN DIEGO, May 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed its previously announced private offering of $517.5 million... More...>>
04/26/20176:48PMPRNUSNeurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering
Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering PR Newswire SAN DIEGO, April 26, 2017 SAN DIEGO, April 26, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the pricing of its offering of $450.0 million aggregate principal amount of 2.25% convertible... More...>>
04/25/20174:01PMPRNUSNeurocrine Announces Proposed Convertible Senior Notes Offering
Neurocrine Announces Proposed Convertible Senior Notes Offering PR Newswire SAN DIEGO, April 25, 2017 SAN DIEGO, April 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible... More...>>
04/21/20176:00AMPRNUSNeurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology...
Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations PR Newswire SAN DIEGO, April 21, 2017 SAN DIEGO... More...>>
04/11/20175:37PMPRNUSNeurocrine Announces FDA Approval of INGREZZA™ (valbenazine) Capsules as the First and Only Approved Treatment for Adults w...
Neurocrine Announces FDA Approval of INGREZZA™ (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) (with multimedia) Provides significant and rapid reduction in involuntary movements with simple once-daily dosing Enables treatment of TD with commonly prescribed psychiatric... More...>>
04/11/20174:52PMPRNUSNeurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults w...
Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) Provides significant and rapid reduction in involuntary movements with simple once-daily dosing Enables treatment of TD with commonly prescribed psychiatric medication... More...>>
04/07/20178:00AMPRNUSAbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual...
AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids - Elagolix, with or without add-back therapy, showed effective and rapid reduction of heavy menstrual bleeding compared to placebo in women with uterine fibroids... More...>>
03/21/20178:59AMPRNUSNeurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA...
Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia - Phase III study conducted in patients with tardive dyskinesia shows significant and meaningful reduction in symptoms with INGREZZA - INGREZZA... More...>>
02/14/20174:01PMPRNUSNeurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017
Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 INGREZZATM New Drug Application PDUFA Action Date of April 11, 2017 Acquired U.S. Rights to Opicapone for Parkinson's Disease Elagolix New Drug Application Submission for Endometriosis Expected in Third Quarter of 2017 Two Phase... More...>>
02/09/20174:01PMPRNUSNeurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone
Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone Expands Movement Disorder Franchise with Rights to Commercialize Late Stage Asset for Parkinson's Disease ONGENTYS® (opicapone) Approved in Europe in June 2016 Neurocrine to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm... More...>>
02/07/20171:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results Conference Call and Webcast Scheduled for Tuesday, February 14, 2017 PR Newswire SAN DIEGO, Feb. 7, 2017 SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20170623 15:43:16